ArticlePloS one2011
Cost-effectiveness of 2009 pandemic influenza A(H1N1) vaccination in the United States.
Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 7 syntheses or guidelines pooled it, 55 citations in OpenAlex.
- Use of Health State Utility Values in Cost-Utility Analyses of Selected Infectious Diseases in Aging Populations: A Systematic Review and Critical Appraisal.PharmacoEconomics - open · 2026Pooled it
- The Use of Expert Elicitation among Computational Modeling Studies in Health Research: A Systematic Review.Medical decision making : an international journal of the Society for Medical Decision Making · 2022Pooled it
- Lessons from past pandemics: a systematic review of evidence-based, cost-effective interventions to suppress COVID-19.Systematic reviews · 2022Pooled it
- Pooled it
- Economic evaluation of pediatric influenza immunization program compared with other pediatric immunization programs: A systematic review.Human vaccines & immunotherapeutics · 2016Pooled it
- Effectiveness and harms of seasonal and pandemic influenza vaccines in children, adults and elderly: a critical review and re-analysis of 15 meta-analyses.Human vaccines & immunotherapeutics · 2012Pooled it
- Systematic review of economic evaluations of preparedness strategies and interventions against influenza pandemics.PloS one · 2012Pooled it
- PRRSV Fetal Infection in Pigs as a Risk Factor for the Emergence of More Efficient Zoonotic Hosts for Swine-Origin Influenza Virus.Veterinary sciences · 2026Article
- Economic Impacts of Initiating Vaccination at 3 Months vs. 6 Months in an Influenza Pandemic in the United States.Vaccines · 2025Article
- Respiratory Syncytial Virus Sequelae Among Adults in High-Income Countries: A Systematic Literature Review and Meta-analysis.Infectious diseases and therapy · 2024Review
- A comparative analysis of control measures on-board ship against COVID-19 and similar novel viral respiratory disease outbreak: Quarantine ship or disembark suspects?Medical journal, Armed Forces India · 2021Article
- Natural outbreaks and bioterrorism: How to deal with the two sides of the same coin?Journal of global health · 2020Review
- Costs and benefits of interventions aimed at major infectious disease threats: lessons from the literature.The European journal of health economics : HEPAC : health economics in prevention and care · 2020Review
- Impact of quadrivalent influenza vaccines in Brazil: a cost-effectiveness analysis using an influenza transmission model.BMC public health · 2020Article
- Cost-effectiveness of increased influenza vaccination uptake against readmissions of major adverse cardiac events in the US.PloS one · 2019Article
- Cost-effectiveness of Strategies for Offering Influenza Vaccine in the Pediatric Emergency Department.JAMA pediatrics · 2018Article
- Epidemiological and economic impact of pandemic influenza in Chicago: Priorities for vaccine interventions.PLoS computational biology · 2017Article
- Impact of quadrivalent influenza vaccine on public health and influenza-related costs in Australia.BMC public health · 2016Article
- A model-based economic analysis of pre-pandemic influenza vaccination cost-effectiveness.BMC infectious diseases · 2014Article
- Vaccination strategies for future influenza pandemics: a severity-based cost effectiveness analysis.BMC infectious diseases · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPandemic influenza A(H1N1) (pH1N1) was first identified in North America in April 2009. Vaccination against pH1N1 commenced in the U.S. in October 2009 and continued through January 2010. The objective of this study was to evaluate the cost-effectiveness of pH1N1 vaccination. METHODOLOGY: A computer simulation model was developed to predict costs and health outcomes for a pH1N1 vaccination program using inactivated vaccine compared to no vaccination. Probabilities, costs and quality-of-life weights were derived from emerging primary data on pH1N1 infections in the US, published and unpublished data for seasonal and pH1N1 illnesses, supplemented by expert opinion. The modeled target population included hypothetical cohorts of persons aged 6 months and older stratified by age and risk. The analysis used a one-year time horizon for most endpoints but also includes longer-term costs and consequences of long-term sequelae deaths. A societal perspective was used. Indirect effects (i.e., herd effects) were not included in the primary analysis. The main endpoint was the incremental cost-effectiveness ratio in dollars per quality-adjusted life year (QALY) gained. Sensitivity analyses were conducted.
resultsFor vaccination initiated prior to the outbreak, pH1N1 vaccination was cost-saving for persons 6 months to 64 years under many assumptions. For those without high risk conditions, incremental cost-effectiveness ratios ranged from $8,000-$52,000/QALY depending on age and risk status. Results were sensitive to the number of vaccine doses needed, costs of vaccination, illness rates, and timing of vaccine delivery.
conclusionsVaccination for pH1N1 for children and working-age adults is cost-effective compared to other preventive health interventions under a wide range of scenarios. The economic evidence was consistent with target recommendations that were in place for pH1N1 vaccination. We also found that the delays in vaccine availability had a substantial impact on the cost-effectiveness of vaccination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.